Suresh Durgam, MD, Receives ISCDD Leadership Award at Annual Meeting Suresh Durgam, MD, honored with the ISCDD Leadership Award at the 24th Annual Meeting, recognizing his contributions to CNS drug development.

Suresh Durgam, MD, Receives ISCDD Leadership Award at Annual Meeting #USA #Las_Vegas #CNS_Drug_Development #Suresh_Durgam #ISCDD_Awards

Illimis Therapeutics Secures $42 Million to Propel CNS and Immune Disease Innovations Illimis Therapeutics has successfully closed a Series B funding round, raising $42 million to accelerate the development of its CNS and immune disease drug pipeline, underscoring strong investor confidence.

Illimis Therapeutics Secures $42 Million to Propel CNS and Immune Disease Innovations #South_Korea #Seoul #CNS_Drug_Development #Illimis_Therapeutics #GAIA_platform

Transneural Therapeutics Appoints Renowned CNS Specialist to Lead Drug Development Efforts Transneural Therapeutics introduces Dr. Mark A. Demitrack as its new Chief Research and Development Officer, emphasizing his expertise in CNS drug development.

Transneural Therapeutics Appoints Renowned CNS Specialist to Lead Drug Development Efforts #USA #Seattle #CNS_Drug_Development #Transneural_Therapeutics #Mark_A._Demitrack

ISCDD Honors Dr. Sharon Mates, PhD, and Dr. Steven Paul, MD with Leadership Award At the 23rd Annual Meeting, ISCDD presented its Leadership Award to Dr. Sharon Mates and Dr. Steven Paul for their contributions to CNS drug development.

ISCDD Honors Dr. Sharon Mates, PhD, and Dr. Steven Paul, MD with Leadership Award #USA #Las_Vegas #CNS_Drug_Development #Sharon_Mates #Steven_Paul